RBN-3143 is a potent and NAD+-competitive catalytic PARP14 inhibitor with an IC 50 value of 4 nM. RBN-3143 inhibits PARP14-mediated ADP-ribosylation and stabilizes PARP14 in cell lines. RBN-3143 can be used in research of lung inflammation In Vivo RBN-3143 (5 μg; intranasal administration) can improve steroid-resistant asthma mouse models . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mouse of asthma models Dosage: 5 ug Administration: Intranasal administration Result: Suppressed the accumulation of alarmins TSLP, IL-33, and IL-25. Form:Solid IC50& Target:PARP14 4 nM (IC 50 ) PARP10 1600 nM (IC 50 ) PARP15 4200 nM (IC 50 ) PARP4 42700 nM (IC 50 ) PARP3 >100000 nM (IC 50 ) PARP2 >100000 nM (IC 50 ) PARP1 >100000 nM (IC 50 )